ASP7517 + pembrolizumab

ASP7517 + pembrolizumab is an investigational combination therapy being developed for the treatment of advanced solid tumors known to express the WT1 antigen. ASP7517 is a therapeutic targeting WT1 (Wilms' Tumor 1 protein), while pembrolizumab is a widely approved PD-1 immune checkpoint inhibitor monoclonal antibody (marketed as KEYTRUDA). The mechanism of action involves ASP7517 modulating WT1 to stimulate anti-tumor immune responses, and pembrolizumab blocking the PD-1 receptor on immune cells to enhance T-cell mediated cancer cell killing. This combination aims to increase the immunogenicity of tumors and boost anti-tumor efficacy. The developer is conducting clinical trials in participants with advanced, unresectable, or metastatic solid tumor malignancies, particularly those confirmed to express WT1. The main diseases studied include colon/rectal cancer, melanoma, and ovarian cancer.

Other names

ASP-7517ASP7517ASP 7517pembrolizumab